Vanguard Global Advisers
TENX icon

Vanguard Global Advisers’s Tenax Therapeutics TENX Stock Holding History

Vanguard Global Advisers’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176K Buy
12,110
+8,811
+267% +$113K ﹤0.01% 2553
2026
Q1 		$52.8K Buy
+3,299
New +$44.6K ﹤0.01% 2996

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Global Advisers's TENX Position: Q2 2026 in Review

Vanguard Global Advisers increased its Tenax Therapeutics (TENX) stake by 267% in Q2 2026, buying an estimated $113K and bringing the position to 12,110 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #2553.

Vanguard Global Advisers first reported a position in TENX in Q1 2026 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Vanguard Global Advisers held 12,110 shares of Tenax Therapeutics worth $176K as of Q2 2026.
  • Vanguard Global Advisers bought 8,811 Tenax Therapeutics shares in Q2 2026, an estimated $113K.
  • Tenax Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2553 holding.
  • Vanguard Global Advisers first reported a position in Tenax Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.